Alan J. Wein, MD, PhD (hon), FACS, Author at Grand Rounds in Urology

Alan J. Wein, MD, PhD (hon), FACS

Alan J. Wein, MD, PhD (hon), FACS, is Professor of Clinical Urology and Director of Business Development and Mentoring at the Desai Sethi Institute of Urology at the University of Miami Miller School of Medicine. He is Emeritus Professor of Urology/Surgery and Emeritus Chief of Urology and Program Director of the Perelman School of Medicine at the University of Pennsylvania.

Dr. Wein received his undergraduate degree from Princeton University and completed medical school, surgery, basic research, and urology training at the University of Pennsylvania (Penn). After serving in the army following his training, he returned to Penn where he ultimately became Chief of Urology and Director of the Residency Program (for 38 and 44 years, respectively). Dr. Wein holds an honorary PhD from the University of Patras, Greece and was conferred an honorary professorship by the Institute of Urology, Russian Ministry of Health.

Dr. Wein’s primary interests include the physiology and pharmacology of the lower urinary tract, evaluation and management of urinary incontinence and all types of lower urinary tract and pelvic floor dysfunction; problems with prostate enlargement and obstruction; and the evaluation and management of prostate, bladder, and kidney cancer. He has received numerous awards and honors for excellence in the field of urology and has been recognized nationally and internationally through his many affiliations and professional memberships. These include the American Association of Genitourinary Surgeons (AAGUS), the Clinical Society of Genitourinary Surgeons (CSGUS); the American Surgical Association; the Society of Surgical Oncology; the Society of Urologic Oncology (where he is a founding member); the Society of Pelvic Surgeons; Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU); the International Continence Society (ICS); Société Internationale d’Urologie (SIU); the American Urological Association (AUA); the European Association of Urology (EAU); and the Royal Society of Medicine.

Dr. Wein’s most notable awards include the Urodynamics Society Lifetime Achievement Award; the F. Brantley Scott Award of the American Foundation for Urologic Diseases; the Hugh Hampton Young Award of the AUA; the Ferdinand C. Valentine Award of the New York Academy of Medicine; the National Association for Continence Continence Care Champion Award; Lifetime Achievement Awards from SUFU, the ICS, and the SIU; the Ellis Island Medal of Honor; and the Keyes Medal by the AAGUS, which is recognized as the greatest individual citation in the specialty, awarded for outstanding contributions in the advancement of urology. Most recently, an annual mentorship award in his name has been commissioned by SUFU and another by the division of urology at Penn. Dr. Wein has authored or co-authored over 1,000 papers and book chapters, held multiple editorial positions on scientific journals and has edited or co-edited over 35 books. He is currently the editor-in-chief of Neurourology and Urodynamics and Urology Case Reports. Dr. Wein was editor-in-chief of the ninth, 10th, and 11th editions of Campbell-Walsh Urology, the gold standard textbook in the field and the name of the 12th and succeeding editions has been changed to Campbell-Walsh-Wein Urology to reflect his contributions to the field. Two chairs have been raised and named in his honor in the division of urology, department of surgery at the University of Pennsylvania Perelman School of Medicine.

Disclosures:

Talks by Alan J. Wein, MD, PhD (hon), FACS

OAB – “Tier 2” Management

Posted by Alan J. Wein, MD, PhD (hon), FACS | Sep 2024

Alan J. Wein, MD, PhD (hon), FACS, explores the pharmacological management of overactive bladder (OAB), focusing on antimuscarinic medications and beta-3 agonists. In this 13-minute presentation, Wein stresses the importance of setting realistic treatment goals for patients, as no current therapy cures OAB but can manage symptoms. He recommends combining behavioral and drug therapy to achieve better outcomes.
Wein discusses antimuscarinic, anticholinergic, and Beta-3 agonist medications in detail. The efficacy of these drugs varies. Overall, while both drug classes offer benefits in managing OAB, the choice of therapy should consider side effects, patient age, and cognitive risks. His presentation concludes with the recommendation that beta-3 agonists may be a safer first-line therapy due to their favorable side-effect profile.

Alan J. Wein, MD, PhD (hon), FACS

Talks by Alan J. Wein, MD, PhD (hon), FACS

OAB – “Tier 2” Management

Join the GRU Community

You have Successfully Subscribed!